Short answer
Kymera Therapeutics, Inc. (KYMR) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 2025 and full-year fiscal 2025 earnings announced February 26, 2026.
Kymera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 and full-year fiscal 2025 earnings announced February 26, 2026
- Full financials in Exhibit 99.1 press release: not "filed," limiting legal liability for the disclosure
- Reg FD-style furnishing means results are public but not subject to Exchange Act Section 18 litigation risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kymera Therapeutics, Inc. 8-K filings
Get the next KYMR 8-K as it lands
Follow KYMR for push alerts, or ask the research agent what this filing means.